Sitagliptin may not control blood sugar during bypass surgery in diabetics: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2020-12-30 06:00 GMT | Update On 2020-12-30 09:49 GMT
Advertisement
USA: Perioperative administration of sitagliptin in diabetes patients undergoing bypass surgery does not prevent hyperglycemia or complications, finds a recent study in the journal Diabetes, Obesity and Metabolism. The sitagliptin therapy, however, reduced daily insulin requirements when the patient shifted to regular ward.
Guillermo E Umpierrez, Department of Medicine, Emory University, Atlanta, Georgia, and colleagues assessed whether sitagliptin treatment before surgery and during the hospital stay can help in preventing and reducing the severity of perioperative hyperglycemia in type 2 diabetes (T2D) patients undergoing coronary artery bypass graft (CABG) surgery.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.